Columbia Laboratories (CBRX) Down 55% On FDA Rejection
Shares of Columbia Laboratories (NASDAQ: CBRX) dropped 55% when the company and partner Watson Pharmaceuticals announced that confirmed that the Advisory Committee for Reproductive Health Drugs of the U.S. Food and Drug Administration (FDA) did not recommend approval of progesterone vaginal…
Shares of Columbia Laboratories (NASDAQ: CBRX) dropped 55% when the company and partner Watson Pharmaceuticals announced that confirmed that the Advisory Committee for Reproductive Health Drugs of the U.S. Food and Drug Administration (FDA) did not recommend approval of progesterone vaginal gel 8% for the reduction of risk of preterm birth in women with short uterine cervical length at the mid-trimester of pregnancy. While panel members generally agreed that progesterone vaginal gel 8% is safe, the panel stated that more information is needed to support approval.
Contact [email protected] for any questions or corrections.

